[go: up one dir, main page]

MA32876B1 - Anticorps dirigés contre l'angiopoïétine 2 humaine - Google Patents

Anticorps dirigés contre l'angiopoïétine 2 humaine

Info

Publication number
MA32876B1
MA32876B1 MA33908A MA33908A MA32876B1 MA 32876 B1 MA32876 B1 MA 32876B1 MA 33908 A MA33908 A MA 33908A MA 33908 A MA33908 A MA 33908A MA 32876 B1 MA32876 B1 MA 32876B1
Authority
MA
Morocco
Prior art keywords
antibodies against
human
against angiopoietin
antibodies
angiopoietin
Prior art date
Application number
MA33908A
Other languages
Arabic (ar)
English (en)
Inventor
Ulrich Brinkmann
Remko Albert Griep
Klaus Kaluza
Anita Kavlie
Christian Klein
Joerg Thomas Regula
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40585738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32876(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32876B1 publication Critical patent/MA32876B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES ANTICORPS DIRIGÉS CONTRE L'ANGIOPOÏÉTINE 2 HUMAINE (ANTICORPS ANTI-ANG-2), LEURS MÉTHODES DE PRODUCTION, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS ANTICORPS ET LEURS UTILISATIONS.
MA33908A 2008-12-16 2011-06-02 Anticorps dirigés contre l'angiopoïétine 2 humaine MA32876B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08021835 2008-12-16
PCT/EP2009/008930 WO2010069532A1 (fr) 2008-12-16 2009-12-14 Anticorps dirigés contre l'angiopoïétine 2 humaine

Publications (1)

Publication Number Publication Date
MA32876B1 true MA32876B1 (fr) 2011-12-01

Family

ID=40585738

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33908A MA32876B1 (fr) 2008-12-16 2011-06-02 Anticorps dirigés contre l'angiopoïétine 2 humaine

Country Status (33)

Country Link
US (12) US8133979B2 (fr)
EP (1) EP2379592B1 (fr)
JP (2) JP5559191B2 (fr)
KR (2) KR101445518B1 (fr)
CN (3) CN103739709B (fr)
AR (2) AR074756A1 (fr)
AU (1) AU2009328613B2 (fr)
BR (2) BRPI0923434A2 (fr)
CA (2) CA2916481C (fr)
CL (2) CL2011001285A1 (fr)
CR (2) CR20110321A (fr)
CY (1) CY1116264T1 (fr)
DK (1) DK2379592T3 (fr)
EC (2) ECSP11011139A (fr)
ES (1) ES2534635T3 (fr)
HR (1) HRP20150439T1 (fr)
HU (1) HUE024545T2 (fr)
IL (2) IL213039A (fr)
MA (1) MA32876B1 (fr)
MX (1) MX2011005908A (fr)
MY (2) MY155654A (fr)
NZ (2) NZ592856A (fr)
PE (2) PE20140814A1 (fr)
PH (1) PH12013502192B1 (fr)
PL (1) PL2379592T3 (fr)
PT (1) PT2379592E (fr)
RU (2) RU2569461C2 (fr)
SG (1) SG172216A1 (fr)
SI (1) SI2379592T1 (fr)
TW (2) TWI396549B (fr)
UA (2) UA105151C2 (fr)
WO (1) WO2010069532A1 (fr)
ZA (2) ZA201103990B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008346734A1 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
CA2781519A1 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes proteiques contenant une super-helice et/ou une attache et leurs utilisations
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
EP2609111B1 (fr) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Anticorps bispécifiques comprenand un fv fragment stabilisé au disulfure
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN102221615A (zh) * 2011-03-31 2011-10-19 广州华灿医药科技有限公司 一种基于Angiogenin检测的双抗夹心ELISA方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012137993A1 (fr) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Anticorps dirigés contre les angiopoïétines 1 et 2, et leur utilisation
EP2714738B1 (fr) 2011-05-24 2018-10-10 Zyngenia, Inc. Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
CA2850542A1 (fr) 2011-09-30 2013-04-04 Dana-Farber Cancer Institute, Inc. Peptides therapeutiques
EP2812357B1 (fr) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Anticorps et autres hétéromultimères monocaténaires
EP2855531A1 (fr) * 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Anticorps multispécifiques
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
SMT202100621T1 (it) 2012-07-13 2022-01-10 Roche Glycart Ag Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
KR101967345B1 (ko) 2012-10-18 2019-04-09 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
WO2014108854A1 (fr) * 2013-01-09 2014-07-17 Fusimab Ltd. Anticorps anti-hgf et anti-ang2 monospécifiques, et anticorps anti-hgf/anti-ang2 bispécifiques
CA2907249A1 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides therapeutiques
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
CA2907181C (fr) 2013-03-15 2023-10-17 Viktor Roschke Complexes multispecifiques multivalents et monovalents et leurs utilisations
KR102131371B1 (ko) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
AU2014368695A1 (en) * 2013-12-20 2016-04-14 F. Hoffmann-La Roche Ag Combination therapy with an anti-ANG2 antibody and a CD40 agonist
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
AU2015229009B2 (en) 2014-03-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers
US9957333B2 (en) * 2014-04-17 2018-05-01 Case Western Reserve University Anti-CEP antibody or fragment thereof
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
WO2016061551A1 (fr) * 2014-10-17 2016-04-21 Amgen Inc. Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 pour thérapies oculaires
WO2016075035A1 (fr) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anticorps anti-ang2 et méthodes d'utilisation correspondantes
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
BR112017015773A2 (pt) * 2015-01-28 2018-03-27 Pieris Pharmaceuticals Gmbh muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
JP6901400B2 (ja) 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
HK1254093A1 (zh) 2015-08-14 2019-07-12 Allergan, Inc. 仅有重链的pdgf抗体
CA2992602A1 (fr) 2015-09-23 2017-03-30 Genentech, Inc. Variants optimises d'anticorps anti-vegf
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
MA49279A (fr) 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
KR102715397B1 (ko) 2017-03-22 2024-10-10 아센디스 파마 에이에스 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2019164219A1 (fr) * 2018-02-20 2019-08-29 Institute For Basic Science Anticorps anti-angiopoïétine-2 et leurs utilisations
KR102497171B1 (ko) * 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
MX2021004774A (es) 2018-10-29 2021-08-24 Hoffmann La Roche Formulacion de anticuerpos.
JP7177284B2 (ja) * 2019-02-25 2022-11-22 ファームアブシン・インコーポレイテッド 抗ａｎｇ２抗体及びその用途
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
MX2022011752A (es) 2020-03-24 2022-10-18 Genentech Inc Agentes de fijacion a tie2 y metodos de uso.
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
EP4183802A4 (fr) * 2020-06-22 2024-11-06 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-ang-2 et son utilisation
CN116472285A (zh) * 2020-08-07 2023-07-21 南京金斯瑞生物科技有限公司 针对人血管生成素-2的抗体及其用途
EP4228702A1 (fr) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Conjugués protéine-hyaluronane non covalents pour administration oculaire à action prolongée
CA3267341A1 (fr) * 2022-09-19 2024-03-28 Sonoma Biotherapeutics, Inc. Récepteurs antigéniques chimériques spécifiques d'un antigène citrulliné pour cibler des lymphocytes t régulateurs pour traiter l'hidradénite suppurée
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
RU2277411C1 (ru) * 2004-12-15 2006-06-10 Ольга Алексеевна Кост Фармацевтическая композиция для лечения глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
CA2799802A1 (fr) * 2004-12-21 2006-06-29 Astrazeneca Ab Anticorps diriges contre l'angiopoietine 2 et leurs utilisations
US7956160B2 (en) * 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
WO2007033216A2 (fr) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Procedes et compositions pour le traitement et le diagnostic de maladies caracterisees par la fuite vasculaire, l'hypotension, ou un etat procoagulant
KR101371773B1 (ko) 2005-12-15 2014-03-07 아스트라제네카 아베 암 치료를 위한, 안지오포이에틴-2 길항자와 ｖｅｇｆ-ａ,ｋｄｒ 및/또는 ｆｌｔ1 길항자의 조합물
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP5259423B2 (ja) * 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド ドメイン抗体構築物
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
SMT202100621T1 (it) * 2012-07-13 2022-01-10 Roche Glycart Ag Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari

Also Published As

Publication number Publication date
CN102746400A (zh) 2012-10-24
CY1116264T1 (el) 2017-02-08
WO2010069532A1 (fr) 2010-06-24
HRP20150439T1 (hr) 2015-05-22
SG172216A1 (en) 2011-07-28
BR122013022089B1 (pt) 2021-10-13
US8133979B2 (en) 2012-03-13
DK2379592T3 (en) 2015-03-02
HUE024545T2 (hu) 2016-01-28
IL226350A (en) 2016-10-31
CA2916481A1 (fr) 2010-06-24
AU2009328613B2 (en) 2013-09-05
US20180282404A1 (en) 2018-10-04
CR20130418A (es) 2013-10-04
US20150284457A1 (en) 2015-10-08
UA103912C2 (uk) 2013-12-10
KR20130103822A (ko) 2013-09-24
JP5814317B2 (ja) 2015-11-17
BRPI0923434A2 (pt) 2017-09-19
ZA201307297B (en) 2019-07-31
ES2534635T3 (es) 2015-04-27
UA105151C2 (uk) 2014-04-10
RU2013140625A (ru) 2015-03-10
US20120142091A1 (en) 2012-06-07
IL213039A0 (en) 2011-07-31
JP5559191B2 (ja) 2014-07-23
TW201026328A (en) 2010-07-16
CL2011001285A1 (es) 2011-09-16
US20130156789A1 (en) 2013-06-20
US20170029493A1 (en) 2017-02-02
PE20120551A1 (es) 2012-05-21
RU2011129204A (ru) 2013-01-27
US9109027B2 (en) 2015-08-18
EP2379592B1 (fr) 2015-02-11
MY155654A (en) 2015-11-13
PE20140814A1 (es) 2014-07-10
US9340609B2 (en) 2016-05-17
SI2379592T1 (sl) 2015-06-30
CR20110321A (es) 2011-07-14
ZA201103990B (en) 2016-01-27
PL2379592T3 (pl) 2015-07-31
CN103739709A (zh) 2014-04-23
NZ600005A (en) 2012-08-31
US9073986B2 (en) 2015-07-07
AR074756A1 (es) 2011-02-09
RU2569107C2 (ru) 2015-11-20
PH12013502192A1 (en) 2015-10-12
MY158438A (en) 2016-10-14
BR122013022089A2 (pt) 2019-05-28
CN102257008A (zh) 2011-11-23
US20210388071A1 (en) 2021-12-16
CA2744624A1 (fr) 2010-06-24
AU2009328613A1 (en) 2010-06-24
US20120141500A1 (en) 2012-06-07
KR20110084536A (ko) 2011-07-25
JP2014000089A (ja) 2014-01-09
US8361747B2 (en) 2013-01-29
ECSP11011139A (es) 2011-07-29
HK1195775A1 (zh) 2014-11-21
ECSP13011139A (es) 2014-10-31
IL213039A (en) 2015-03-31
CL2012003054A1 (es) 2012-12-14
US20200262904A1 (en) 2020-08-20
US20140065707A1 (en) 2014-03-06
EP2379592A1 (fr) 2011-10-26
IL226350A0 (en) 2013-06-27
TWI482631B (zh) 2015-05-01
CN102746400B (zh) 2015-12-16
PH12013502192B1 (en) 2015-10-12
PT2379592E (pt) 2015-03-24
KR101445518B1 (ko) 2014-10-01
AR092487A2 (es) 2015-04-22
JP2012511897A (ja) 2012-05-31
CA2916481C (fr) 2018-05-15
HK1172349A1 (zh) 2013-04-19
MX2011005908A (es) 2011-06-20
US20140065151A1 (en) 2014-03-06
NZ592856A (en) 2012-06-29
CN103739709B (zh) 2016-08-24
US8399626B2 (en) 2013-03-19
WO2010069532A8 (fr) 2012-05-10
TW201322996A (zh) 2013-06-16
TWI396549B (zh) 2013-05-21
RU2569461C2 (ru) 2015-11-27
US20100159587A1 (en) 2010-06-24
US20230227543A1 (en) 2023-07-20
KR101381012B1 (ko) 2014-04-11
CA2744624C (fr) 2018-01-02

Similar Documents

Publication Publication Date Title
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
CY1118984T1 (el) Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων
MA33892B1 (fr) Anticorps anti-her3, et leurs utilisations
MA34172B1 (fr) Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
CO6571886A2 (es) Antagonistas de pcsk9
MA32713B1 (fr) Anticorps anti-egfr/anti-igf-1r bispecifiques
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MY164646A (en) Nicotine lozenge compositions
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
TW200716646A (en) (S)-N-methylnaltrexone
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MX385354B (es) Sales de xantilio 3,6-disustituidas.
DK1753440T3 (da) Oral administrationsform indeholdende probiotiske bakterier
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
CY1116840T1 (el) Χρηση 24-norudca